evidence: In parallel to the work done to restart medicine production, Pfizer has also begun storing non-production related materials, such as packaging components, in a new warehouse secured as a temporary replacement to its HiRise warehouse, which was most affected by the tornado. After conducting all required quality assurance processes, Pfizer continues to package and release to distribution centers all medicines that were not impacted by the tornado. Pfizer has also initiated knowledge and documentation transfers (tech transfers) to facilitate product manufacturing at other sterile injectable sites in its network to accelerate the resupply of medicines. [...] This release contains forward-looking information about Pfizer’s ongoing efforts to recover from the damage caused by a tornado to Pfizer’s Rocky Mount, North Carolina manufacturing facility, including the resumption of production on its manufacturing lines, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to complete repairs to the facility, replacing damaged raw material and supplies and restoring full function to the site in the anticipated timeframe or at all; other business effects, including the effects of industry, market, economic, political or regulatory conditions; uncertainties regarding the impact of COVID-19; and competitive developments.